459 related articles for article (PubMed ID: 28607134)
1. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
2. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53.
Irish JM; Anensen N; Hovland R; Skavland J; Børresen-Dale AL; Bruserud O; Nolan GP; Gjertsen BT
Blood; 2007 Mar; 109(6):2589-96. PubMed ID: 17105820
[TBL] [Abstract][Full Text] [Related]
3. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
4. Role of p53 in regulation of hematopoiesis in health and disease.
Barajas S; Cai W; Liu Y
Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
[TBL] [Abstract][Full Text] [Related]
5. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
6. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
[TBL] [Abstract][Full Text] [Related]
7. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact and targeting of CRM1 in acute myeloid leukemia.
Kojima K; Kornblau SM; Ruvolo V; Dilip A; Duvvuri S; Davis RE; Zhang M; Wang Z; Coombes KR; Zhang N; Qiu YH; Burks JK; Kantarjian H; Shacham S; Kauffman M; Andreeff M
Blood; 2013 May; 121(20):4166-74. PubMed ID: 23564911
[TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
[TBL] [Abstract][Full Text] [Related]
10. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
11.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
12. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
13. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications.
Takahashi S
J Hematol Oncol; 2011 Apr; 4():13. PubMed ID: 21453545
[TBL] [Abstract][Full Text] [Related]
14. Impact of genomics in the clinical management of patients with cytogenetically normal acute myeloid leukemia.
Falini B; Martelli MP
Best Pract Res Clin Haematol; 2015; 28(2-3):90-7. PubMed ID: 26590764
[TBL] [Abstract][Full Text] [Related]
15. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
Ånensen N; Hjelle SM; Van Belle W; Haaland I; Silden E; Bourdon JC; Hovland R; Taskén K; Knappskog S; Lønning PE; Bruserud Ø; Gjertsen BT
Oncogene; 2012 Mar; 31(12):1533-45. PubMed ID: 21860418
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Haaland I; Opsahl JA; Berven FS; Reikvam H; Fredly HK; Haugse R; Thiede B; McCormack E; Lain S; Bruserud O; Gjertsen BT
Mol Cancer; 2014 May; 13():116. PubMed ID: 24885082
[TBL] [Abstract][Full Text] [Related]
17. Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G; Gagliardi A; Mezzasoma F; Rocchio F; Tini V; Bigerna B; Sportoletti P; Caruso S; Marra A; Peruzzi S; Petito E; Spinozzi G; Shacham S; Landesman Y; Quintarelli C; Gresele P; Locatelli F; Martelli MP; Falini B; Brunetti L
Blood Adv; 2022 Nov; 6(22):5938-5949. PubMed ID: 36037515
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
19. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
[TBL] [Abstract][Full Text] [Related]
20. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
